

PROMOTING SAFETY OF MEDICINES FOR CHILDREN



World Health
Organization

WHO LIBRARY CATALOGUING-IN-PUBLICATION DATA:

Promoting safety of medicines for children

1.Pharmaceutical preparations - administration and dosage.
2.Child. 3.Infant. 4.Safety. 5.Drug monitoring. 6.Adverse drug reaction reporting systems. 7.Guidelines. I.World Health Organization.

ISBN 978-92-4-156343-7

(NLM classification: WS 366)

© WORLD HEALTH ORGANIZATION 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France

PROMOTING SAFETY OF MEDICINES FOR CHILDREN



**World Health
Organization**

Acknowledgements

This publication was developed following a recommendation of the WHO Advisory Committee for the Safety of Medicinal Products. The draft manuscript has been widely circulated and discussed at several consultations with international experts in regulatory affairs and in paediatrics. WHO is particularly grateful to Nilima A. Kshirsagar, India, Hansjörgen Seyberth, Germany, and the Karolinska, Sweden for their initial input to this manuscript. Sincere thanks are also due to the following persons for their valued expertise in evaluating this publication.

Niamh Arthur, Ireland, Jürgen Beckmann, Germany, Ulf Bergman, Sweden, David Coulter, New Zealand, Gerald Dal Pan, USA, I. Ralph Edwards, Sweden, Murilo Freitas Dias, Brazil, Kenneth Hartigan-Go, Philippines, Li Dakui, China, Sten Olsson, Sweden, June Raine, UK, Anders Rane, Sweden, Gunilla Sjölin-Forsberg, Sweden, Rachida Soulaymani-Bencheikh, Morocco.

Technical editing: Mary R. Couper, WHO and Susan Kaplan
Art direction: Guillaume Desbiolles, Calleo Portage
Assistance in production of document: Caroline Scudamore, WHO

WHO expresses its sincere appreciation to the Government of Sweden for providing financial support to finance the drafting of the manuscript.

Promoting safety of medicines for children

1	Introduction	p. 7
2	Current situation	p. 9
2.1	Problems with medicine treatment in children and adolescents around the world	p. 9
2.2	Consequences of present status of the use of medicines in children (environmental aspects)	p. 10
2.3	General risk factors that predispose children to develop an adverse reaction to a medicine (medical aspects)	p. 11
2.4	Differences between paediatric populations and adults	p. 12
2.5	The need for additional, independent studies on the development of paediatric medicines	p. 16
2.6	Current legal and regulatory framework	p. 17
2.7	Consequences of the lack of studies of medicines development in children and authorization of paediatric medicines	p. 19
3	The essential role of safety monitoring in the life-cycle of a medicine	p. 21
3.1	Pre-marketing assessment of medicine safety	p. 21
3.2	Post-marketing monitoring of medicine safety for medicines already on the market including those used "off-label"	p. 22
3.3	Benefit-to-risk considerations in children	p. 23
4	Medication errors	p. 25
4.1	Increased risk of medication errors in children	p. 25
4.2	Incidence of medication errors	p. 26
5	Primary responsibility of stakeholders	p. 29
6	Guidance: measures to be taken	p. 33
6.1	Improvement of awareness among stakeholders	p. 34
6.2	Methods, approaches and infrastructure for an effective system for medicine safety monitoring at the national level	p. 35
6.3	Implementation of methods and structural changes for effective monitoring of medicine safety at the national level	p. 36
6.4	Impact measurement and audit	p. 37
7	Measures to be taken by WHO	p. 39
References		p. 41
Annex I	Pharmacovigilance methods	p. 43
References		p. 50
Annex 2	Recent information on adverse reactions to marketed medicines in children	p. 51
References		p. 57

1

2

3

4

5

6

7

Annex 1

Annex 2

1. INTRODUCTION

Monitoring the safety of medicine use in children is of paramount importance since, during the clinical development of medicines, only limited data on this aspect are generated through clinical trials. Use of medicines outside the specifications described in the licence (e.g. in terms of formulation, indications, contraindications or age) constitutes off-label and off-licence use and these are a major area of concern.

These guidelines are intended to improve awareness of medicine safety issues among everyone who has an interest in the safety of medicines in children and to provide guidance on effective systems for monitoring medicine safety in the paediatric populations. The document will be of interest to all health-care professionals, medicine regulatory authorities, pharmacovigilance centres, academia, the pharmaceutical industry and policy-makers.

Systems for monitoring medicine safety are described in Annex 1 - Pharmacovigilance methods and some examples of recent information on adverse reactions to marketed medicines are discussed in Annex 2.

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible medicine-related problems (1). For the purposes of this document, an adverse reaction to a medicine (ADR) includes not only reactions occurring during normal use of medicines, but also reactions due to errors in medicine administration, non-adherence, overdose, off-label use, drug abuse and adverse effects due to the use of traditional and complementary medicines. It does not address the paediatric use of vaccines. Separate WHO guidelines

1

2

3

4

5

6

7

预览已结束，完整报告链接和二维码

<https://www.yunbaogao.cn/report/index/report?reportId=5>